NewAmsterdam Pha SEC Filings

NewAmsterdam Pharma Company N.V. furnished a current report to let the market know it has posted an updated corporate investor presentation on its website as of September 2, 2025. The presentation, dated the same day, is attached as Exhibit 99.1 and provides investors with the latest corporate information in slide format. The company emphasizes that this material is furnished under Regulation FD, not filed, meaning it is not subject to certain securities law liabilities and is not automatically incorporated into any of its existing or future registration statements or Exchange Act filings unless expressly stated.

Insider sale by NewAmsterdam Pharma Company N.V. officer and director. The reporting person, Louise Frederika Kooij, identified as the company's Chief Accounting Officer and a director, reported a sale of 8,269 ordinary shares on 08/25/2025 at a weighted average price of $24.86 per share. After the reported sale, the filing shows the reporting person beneficially owned 15,000 ordinary shares (direct ownership). The form notes the reported price is a weighted average from multiple transactions priced between $24.74 and $24.92, and that the filer can provide the exact share counts per trade on request.

NewAmsterdam Pharma Company N.V. (NAMSW) insider Louise Kooij filed a Form 144 reporting a proposed sale of 8,269 ordinary shares (nominal value EUR 0.12). The shares were acquired by RSU vesting on 03/26/2025 and the broker listed is Cooperatieve Rabobank U.A., Utrecht. The filing shows an approximate aggregate market value of $208,296.11 and indicates an intended sale on 08/25/2025 on the Nasdaq Global Market. The issuer's total shares outstanding are reported as 112,628,458. The filer attests there is no undisclosed material adverse information and includes the standard signature/representation language required by the form.

Insider sales totaling 100,000 ordinary shares were reported by Johannes J.P. Kastelein, Chief Scientific Officer and Director of NewAmsterdam Pharma Co N.V. (NAMSW). The Form 4 shows three dispositions: 50,000 shares sold on 08/21/2025 at a weighted average price of $24.29, 42,342 shares sold on 08/22/2025 at a weighted average price of $25.08, and 7,658 shares sold on 08/22/2025 at a weighted average price of $25.49. After these transactions, the reporting person beneficially owns 69,302 ordinary shares indirectly through Futurum B.V., over which he reports sole voting and investment control. The filing includes weighted-average price ranges for each sale batch and is signed by a power of attorney on 08/25/2025.

NewAmsterdam Pharma Company N.V. (NAMSW) Rule 144 notice: The filing reports a proposed sale of 100,000 ordinary shares (nominal value EUR 0.12) through ABN AMRO on the Nasdaq Global Market with an aggregate market value of $2,500,000.00. The filer acquired these shares by option exercise on 03/24/2025 from NewAmsterdam Pharma Company N.V., paid in cash on 03/11/2025. The filing shows prior sales by the same person of 50,000 shares on 08/21/2025 for $1,214,613.94 and 50,000 shares on 08/22/2025 for $1,257,092.68. Total shares outstanding are reported as 112,628,458. The filer certifies no undisclosed material adverse information.

Amendment No. 5 to a Schedule 13D reports the current beneficial ownership by a group of Frazier Life Sciences entities in NewAmsterdam Pharma Company N.V. (Ordinary Shares, EUR0.12 par). Together the reporting persons beneficially own 7,327,937 shares (6.5% of the class), which the filing explains consists of 6,827,604 ordinary shares and 500,333 ordinary shares issuable upon exercise of warrants. Key individual holdings disclosed include Sponsor: 3,801,000 shares plus 167,000 warrants; Frazier Life Sciences Public Fund, L.P.: 5,587,957 shares; Frazier Life Sciences Public Overage Fund, L.P.: 2,975,757 shares; Frazier Life Sciences XI, L.P.: 1,174,815 shares; and Frazier Life Sciences XII, L.P.: 59,647 shares. The filing states that working capital funded certain purchases and corrects prior attributions of beneficial ownership for some investment committee members. It also notes no transactions by the reporting persons in the past 60 days except as listed in Exhibit 10.1.

NewAmsterdam Pharma Company N.V. reports that the European Medicines Agency has validated its Marketing Authorization Application for obicetrapib 10 mg as monotherapy and for a 10 mg obicetrapib plus 10 mg ezetimibe fixed-dose combination. These treatments are aimed at patients with primary hypercholesterolemia, including both heterozygous familial and non-familial cases, as well as mixed dyslipidemia.

The validation allows the EMA to begin substantive review of data from the Company’s BROADWAY, BROOKLYN and other Phase 3 clinical trials. The MAA was submitted by A. Menarini International Licensing S.A., which holds an exclusive license with a NewAmsterdam subsidiary and is responsible for European regulatory interactions, commercialization, local development of obicetrapib, and related collaborative activities.

NewAmsterdam Pharma Company N.V. disclosed that its subsidiary, NewAmsterdam Pharma B.V., entered into a Supply Agreement with A. Menarini International Licensing S.A. on August 12, 2025. Under this agreement, the subsidiary will initially act as Menarini’s exclusive supplier of obicetrapib monotherapy and an obicetrapib/ezetimibe fixed-dose combination in bulk tablet form. Menarini must provide periodic volume forecasts, part of which will be binding, and pricing will be based on a defined mark-up over the subsidiary’s cost of goods sold, with periodic adjustments.

The parties will also start a process to transfer manufacturing of these drug products to Menarini or a designated third-party manufacturer. To support that transfer, NewAmsterdam’s subsidiary granted Menarini a non-exclusive, non-transferable license under the company’s patents and know-how to manufacture finished drug products. The Supply Agreement runs for the duration of the existing License Agreement, with rights for early termination in specified cases such as convenience (subject to timing conditions), uncured material breach, insolvency, or extended force majeure.

Form 4 filed for James N. Topper, Director of NewAmsterdam Pharma Co. N.V. (NAMSW). The filing reports a securities transaction dated 08/11/2025 and the reporter's related indirect holdings.

On 08/11/2025 the Form 4 shows a transaction with code P reporting the acquisition of 471 ordinary shares at a weighted average price of $23.9787. The filing also discloses indirect holdings of 3,026,604 shares held by Frazier Life Sciences X, L.P. and 3,801,000 shares held by Frazier Lifesciences Sponsor LLC. Footnotes state the purchased shares were bought at prices ranging from $23.91 to $24.00 and include disclaimers that the reporting person disclaims beneficial ownership except to the extent of his pecuniary interest. The form is signed by an attorney-in-fact dated 08/13/2025.